TRCT
LVTX

Tower Research Capital (TRC)’s LAVA Therapeutics LVTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,460
Closed -$18.1K – 6034
2023
Q4 		$18.1K Sell
11,460
-500
-4% -$714 ﹤0.01% 3712
2023
Q3 		$17.6K Hold
11,960
– – ﹤0.01% 3494
2023
Q2 		$24.3K Buy
+11,960
New +$22.1K ﹤0.01% 3211
2021
Q3 		– Sell
-557
Closed -$6K – 5993
2021
Q2 		$6K Buy
+557
New +$6.9K ﹤0.01% 4633

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tower Research Capital (TRC)'s LVTX Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of LAVA Therapeutics (LVTX) in Q1 2024, closing a stake of 11,460 shares — an estimated $18.1K sold.

Tower Research Capital (TRC) first reported a position in LVTX in Q2 2021 and held it in 4 quarters. The position peaked at $24.3K in Q2 2023. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining LAVA Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 11,460 LAVA Therapeutics shares in Q1 2024, an estimated $18.1K.
  • Tower Research Capital (TRC) first reported a position in LAVA Therapeutics in Q2 2021 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s LAVA Therapeutics position peaked at $24.3K in Q2 2023.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.